ClearPoint Neuro Entered into a Multi-Year License Agreement with UCB for Gene Therapy Drug Delivery


ClearPoint Neuro is eligible to receive success-based milestones. The companies’ focus is to develop drug delivery platforms for Belgian biopharma’s gene therapy portfolio
The agreement enables UCB to use ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products. The agreement also advances UCB’s research and development pipeline in gene therapy
Additionally, ClearPoint Neuro Navigation System received the US FDA clearance, was CE-marked, and was installed in ~65 active sites in North America, the EU, and South America

Ref: ClearPoint Neuro | Image: ClearPoint Neuro

Related News:- Opus Genetics Acquires Two Gene Therapy Candidates from Iveric Bio for the Treatment of Inherited Retinal Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at